FDA blockbuster drug approval plan in October 2021

Compilenewborn

As of September this year, the US FDA has approved a total of 40 innovative drugs, compared with 40 in the same period last year and 53 in the whole year of last year

——Takeda's tyrosine kinase inhibitor Exkivity is the first oral therapy to treat non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutation;

-Tivdak, the tissue factor (TF) targeted drug of Seattle Genetics, is the first antibody-conjugated drug (ADC) for the treatment of cervical cancer;

-AbbVie Qulipta is the first oral calcitonin gene-related peptide (CGRP) receptor antagonist for the preventive treatment of migraine;

--Mirum Pharmaceuticals' oral ASBT inhibitor Livmarli is the first drug to treat cholestatic pruritus in patients with Alagil syndrome (ALGS)

Entering October, a number of drugs will usher in an important review decision by the FDA

Reference source: Biotech Stocks Facing FDA Decision In October 2021